Risk Factors for Severe Outcomes in Patients With Systemic Vasculitis and COVID‐19: A Binational, Registry‐Based Cohort Study-Reference-Cited by-同舟云学术

Risk Factors for Severe Outcomes in Patients With Systemic Vasculitis and COVID‐19: A Binational, Registry‐Based Cohort Study

Published:2021-07-27 Issue:9 Volume:73 Page:1713-1719
ISSN:2326-5191
Container-title:Arthritis & Rheumatology
language:en
Short-container-title:Arthritis Rheumatol

Author:

Rutherford Matthew A.¹^ORCID,Scott Jennifer²,Karabayas Maira³,Antonelou Marilina⁴^ORCID,Gopaluni Seerapani⁵^ORCID,Gray David⁶,Barrett Joe⁶,Brix Silke R.⁷,Dhaun Neeraj⁸^ORCID,McAdoo Stephen P.⁹^ORCID,Smith Rona M.⁵,Geddes Colin C.¹⁰,Jayne David⁵,Luqmani Raashid¹¹,Salama Alan D.¹²,Little Mark A.²,Basu Neil¹³^ORCID,

Affiliation:

1. University of Glasgow and Queen Elizabeth University Hospital Glasgow UK

2. Trinity College Dublin Dublin Ireland

3. NHS Grampian Aberdeen UK

4. University College London London UK

5. University of Cambridge Cambridge UK

6. University of Oxford Oxford UK

7. Manchester University NHS Foundation Trust and University of Manchester Manchester UK

8. University of Edinburgh Edinburgh UK

9. Hammersmith Hospital and Imperial College London London UK

10. Queen Elizabeth University Hospital Glasgow UK

11. Oxford University Hospitals NHS Foundation Trust Oxford UK

12. University College London and Royal Free Hospital London UK

13. University of Glasgow Glasgow UK

Funder

Vifor Pharma

Publisher

Wiley

Subject

Immunology,Rheumatology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/art.41728

Reference22 articles.

1. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

2. World Health Organization.WHO Director‐General’s opening remarks at the media briefing on COVID‐19–11 March 2020. URL:https://www.who.int/dg/speeches/detail/who‐director‐general‐s‐opening‐remarks‐at‐the‐media‐briefing‐on‐covid‐19‐‐‐11‐march‐2020.

3. Immunosuppressive and glucocorticoid therapy for the treatment of ANCA-asssociated vasculitis

4. Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis

5. Dexamethasone in Hospitalized Patients with Covid-19

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Symptoms and Severity of COVID-19 in Patients with Immune-Mediated Inflammatory Diseases: Experience of a University Medical Center;Autoimmune Diseases;2024-03-27

2. COVID-19 outcome is not affected by anti-CD20 or high-titer convalescent plasma in immunosuppressed patients;Scientific Reports;2023-12-01

3. Specific Cellular and Humoral Response after the Third Dose of Anti-SARS-CoV-2 RNA Vaccine in Patients with Immune-Mediated Rheumatic Diseases on Immunosuppressive Therapy;Biomedicines;2023-08-29

4. Managing Immunosuppression in Vasculitis Patients in Times of Coronavirus Disease 2019;Rheumatic Disease Clinics of North America;2023-08

5. COVID‐19 and reported mortality cases among rheumatic disease patients in Kuwait: Data from the Global Rheumatology Alliance registry;International Journal of Rheumatic Diseases;2023-06-07